Mark Sarno

1.2k total citations
28 papers, 910 citations indexed

About

Mark Sarno is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Rheumatology. According to data from OpenAlex, Mark Sarno has authored 28 papers receiving a total of 910 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 4 papers in Rheumatology. Recurrent topics in Mark Sarno's work include Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (10 papers) and Mast cells and histamine (3 papers). Mark Sarno is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (10 papers) and Mast cells and histamine (3 papers). Mark Sarno collaborates with scholars based in United States, Canada and Sweden. Mark Sarno's co-authors include Robert L. Wolfert, Eleftherios P. Diamandis, Iris Simón, Nam W. Kim, William Nowatzke, Thomas Cole, Shaoqiu Zhuo, Laura G. Corral, Harry G. Rittenhouse and Jack Groskopf and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

Mark Sarno

26 papers receiving 877 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Sarno United States 14 247 235 164 162 146 28 910
Anne Fajac France 17 274 1.1× 224 1.0× 83 0.5× 80 0.5× 257 1.8× 40 834
Josip Lukač Croatia 21 261 1.1× 88 0.4× 157 1.0× 202 1.2× 236 1.6× 57 1.1k
M A Forbes United Kingdom 15 423 1.7× 147 0.6× 125 0.8× 133 0.8× 238 1.6× 29 1.1k
Sally B. Coburn United States 13 193 0.8× 118 0.5× 53 0.3× 118 0.7× 143 1.0× 26 715
Timothy J. O’Rourke United States 15 311 1.3× 210 0.9× 70 0.4× 197 1.2× 345 2.4× 34 962
Masaru Ido Japan 18 277 1.1× 126 0.5× 245 1.5× 89 0.5× 200 1.4× 80 1.1k
Renée M. Ned United States 18 296 1.2× 75 0.3× 184 1.1× 125 0.8× 112 0.8× 31 1.3k
Helen Parry United Kingdom 20 358 1.4× 64 0.3× 268 1.6× 208 1.3× 303 2.1× 50 1.4k
Caiyun He China 24 718 2.9× 286 1.2× 187 1.1× 345 2.1× 384 2.6× 98 1.6k
Tsuguru Usui Japan 20 404 1.6× 451 1.9× 63 0.4× 320 2.0× 258 1.8× 91 1.5k

Countries citing papers authored by Mark Sarno

Since Specialization
Citations

This map shows the geographic impact of Mark Sarno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sarno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sarno more than expected).

Fields of papers citing papers by Mark Sarno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Sarno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sarno. The network helps show where Mark Sarno may publish in the future.

Co-authorship network of co-authors of Mark Sarno

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Sarno. A scholar is included among the top collaborators of Mark Sarno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Sarno. Mark Sarno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kim, Nam, et al.. (2024). Validation of Keratin 17 as a tissue biomarker in the diagnosis of upper tract urothelial carcinoma. Human Pathology. 154. 105682–105682.
2.
Morris, Sheldon, Claire Bristow, Michael R. Wierzbicki, et al.. (2020). Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study. The Lancet Infectious Diseases. 21(5). 668–676. 65 indexed citations
3.
Silkoff, Philip E., et al.. (2019). Clinical precision, accuracy, number and durations of exhalations for a novel electrochemical monitor for exhaled nitric oxide. Journal of Breath Research. 14(1). 16011–16011. 4 indexed citations
4.
Schaff, Ulrich Y., et al.. (2016). Novel centrifugal technology for measuring sperm concentration in the home. Fertility and Sterility. 107(2). 358–364.e4. 35 indexed citations
5.
Moul, Judd W., et al.. (2014). NADiA ProsVue Prostate-specific Antigen Slope, CAPRA-S, and Prostate Cancer–specific Survival After Radical Prostatectomy. Urology. 84(6). 1427–1433. 2 indexed citations
6.
Moul, Judd W., Edouard J. Trabulsi, Christopher A. Warlick, et al.. (2014). Impact of NADiA ProsVue PSA slope on secondary treatment decisions after radical prostatectomy. Prostate Cancer and Prostatic Diseases. 17(3). 280–285. 4 indexed citations
7.
8.
Moul, Judd W., Hans Lilja, Raymond Lance, et al.. (2013). Value of NADiA ProsVue on the CAPRA-S nomogram for predicting postprostatectomy clinical recurrence.. Journal of Clinical Oncology. 31(6_suppl). 139–139. 2 indexed citations
9.
10.
11.
Aubin, Sheila M. J., Jennifer Reid, Mark Sarno, et al.. (2011). Prostate Cancer Gene 3 Score Predicts Prostate Biopsy Outcome in Men Receiving Dutasteride for Prevention of Prostate Cancer: Results From the REDUCE Trial. Urology. 78(2). 380–385. 16 indexed citations
12.
Aubin, Sheila M. J., Jennifer Reid, Mark Sarno, et al.. (2010). PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial. The Journal of Urology. 184(5). 1947–1952. 102 indexed citations
13.
Daniels, Lori B., Gail A. Laughlin, Mark Sarno, et al.. (2008). Lipoprotein-Associated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older Population. Journal of the American College of Cardiology. 51(9). 913–919. 83 indexed citations
14.
Simón, Iris, Dionyssios Katsaros, M Massobrio, et al.. (2007). B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecologic Oncology. 106(2). 334–341. 60 indexed citations
15.
Daniels, Lori B., Elizabeth Barrett‐Connor, Mark Sarno, et al.. (2006). Abstract 4036: Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Independently Predicts Incident Coronary Heart Disease (CHD) in an Apparently Healthy Older Population: The Rancho Bernardo Study. Circulation. 114. 1 indexed citations
16.
Nowatzke, William, et al.. (2004). Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark™) and determination of reference intervals on the Hitachi 917 analyzer. Clinica Chimica Acta. 350(1-2). 201–209. 42 indexed citations
17.
McGill, Janet B., et al.. (2004). Circulating 1,5-Anhydroglucitol Levels in Adult Patients With Diabetes Reflect Longitudinal Changes of Glycemia. Diabetes Care. 27(8). 1859–1865. 118 indexed citations
18.
Karavodin, Linda M., et al.. (2003). Toxicology and Toxicokinetics of Acute and Subchronic Administration of Histamine Dihydrochloride in Rats. Drug and Chemical Toxicology. 26(1). 35–49. 10 indexed citations
19.
Middleton, Mark R., Mark Sarno, Sanjiv S. Agarwala, et al.. (2002). Pharmacokinetics of Histamine Dihydrochloride in Healthy Volunteers and Cancer Patients: Implications for Combined Immunotherapy with Interleukin‐2. The Journal of Clinical Pharmacology. 42(7). 774–781. 14 indexed citations
20.
Sarno, Mark, et al.. (2000). Clinical immunogenicity of measles, mumps and rubella vaccine delivered by the Injex jet injector: comparison with standard syringe injection. The Pediatric Infectious Disease Journal. 19(9). 839–842. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anne Fajac Breakdown of academic impact, for papers by Josip Lukač Breakdown of academic impact, for papers by M A Forbes Breakdown of academic impact, for papers by Sally B. Coburn Breakdown of academic impact, for papers by Timothy J. O’Rourke Breakdown of academic impact, for papers by Masaru Ido Breakdown of academic impact, for papers by Renée M. Ned Breakdown of academic impact, for papers by Helen Parry Breakdown of academic impact, for papers by Caiyun He Breakdown of academic impact, for papers by Tsuguru Usui
Rankless by CCL
2026